下気道治療薬市場- 世界の産業規模、シェア、動向、機会、予測、疾患タイプ別、薬剤クラス別、投与経路別、エンドユーザー別、地域別、競合：2020～2030年

下気道治療薬の世界市場規模は、2024年に360億4,000万米ドルで、2030年には589億8,000万米ドルに達し、年間平均成長率（CAGR）8.53％を記録すると予測されています。

この市場成長の原動力となっているのは、肺炎、気管支炎、慢性閉塞性肺疾患（COPD）などの呼吸器系疾患の有病率の上昇といった主要要因です。特に高齢者や免疫不全者のような社会的弱者の間で、これらの疾患の世界の負担が増加していることが、効果的な治療オプションに対する需要を煽っています。さらに、多くの地域で都市化、環境汚染物質への曝露、喫煙率の上昇がこれらの疾患の発生をさらに悪化させており、これが急性と慢性呼吸器感染症に対処する治療の必要性を高めています。また、特に新興国市場における医療インフラの拡充は、診断と治療へのアクセシビリティを高め、呼吸器治療市場の拡大に寄与しています。

主要市場促進要因

主要市場課題

主要市場動向：

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の下気道治療薬市場に与える影響

第5章 顧客の声

第6章 世界の下気道治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 疾患タイプ別（喘息、COPD、肺炎、結核、気管支炎、その他）
  • 薬剤クラス別（抗生物質、非ステロイド性抗炎症薬、咳止め薬、鼻づまり薬、その他）
  • 投与経路別（経口、非経口、その他）
  • エンドユーザー別（病院クリニック、外来診療センター、その他）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第7章 アジア太平洋の下気道治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第8章 欧州の下気道治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第9章 北米の下気道治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第10章 南米の下気道治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第11章 中東・アフリカの下気道治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第12章 市場力学

• 促進要因
• 課題

第13章 市場動向と発展

• 製品上市
• 合併と買収

第14章 世界の下気道治療薬市場：SWOT分析

第15章 ポーターのファイブフォース分析

• 産業内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第16章 PESTEL分析

第17章 競合情勢

• F. Hoffman-La Roche Ltd
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A
• Pfizer Inc.
• GSK plc
• Novartis AG
• AstraZeneca
• Johnson & Johnson
• Sun Pharmaceutical Industries Ltd.
• Merck & Co., Inc

第18章 戦略的提言

第19章 調査会社について・免責事項

The Global Lower Respiratory Tract Therapeutics Market was valued at USD 36.04 billion in 2024 and is projected to reach USD 58.98 billion by 2030, registering a Compound Annual Growth Rate (CAGR) of 8.53%. This market growth is driven by key factors such as the rising prevalence of respiratory diseases like pneumonia, bronchitis, and chronic obstructive pulmonary disease (COPD). The increasing global burden of these conditions, particularly among vulnerable groups like the elderly and immunocompromised individuals, has fueled the demand for effective treatment options. Additionally, urbanization, exposure to environmental pollutants, and higher smoking rates in many regions are further aggravating the incidence of these diseases, which in turn drives the need for therapeutics to address both acute and chronic respiratory infections. The expansion of healthcare infrastructure, especially in developing regions, has also enhanced the accessibility of diagnoses and treatments, contributing to a growing market for respiratory therapeutics.

Key Market Drivers:

Rising Prevalence of Respiratory Disorders The global healthcare landscape is seeing a notable rise in respiratory disorders, particularly lower respiratory tract conditions. Disorders such as chronic obstructive pulmonary disease (COPD), asthma, pneumonia, and bronchitis are becoming more widespread, leading to heightened demand for effective therapeutic solutions. Lower respiratory tract conditions, which significantly affect lung function and overall quality of life, are among the most prevalent and debilitating. These conditions are becoming increasingly common, driven by factors such as urbanization, pollution, tobacco use, and sedentary lifestyles, alongside an aging population more susceptible to respiratory health issues.

Key Market Challenges:

Competition from Generic Drugs The market for lower respiratory tract therapeutics faces considerable challenges from intense competition and the growing availability of generic drugs. As branded therapies become established, generic alternatives often enter the market, offering more cost-effective options for patients. This price competition places pressure on pharmaceutical companies, particularly those marketing patented treatments, as generics provide comparable therapeutic effects at a much lower cost. The widespread use of generic drugs plays a pivotal role in reducing healthcare costs, posing a challenge for branded drug manufacturers to retain market share.

Key Market Trends:

Shift Towards Targeted Therapies There is a significant trend toward the development of targeted therapies in the global lower respiratory tract therapeutics market. This shift is driven by advancements in molecular biology and a deeper understanding of disease mechanisms. Targeted therapies aim to address the root causes of diseases such as COPD and asthma, rather than just alleviating symptoms. For example, biologic agents like monoclonal antibodies are being developed to target specific inflammatory molecules such as interleukins, which are integral in diseases like asthma and COPD. These treatments offer enhanced precision by directly addressing the underlying mechanisms of disease.

Key Market Players:

• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Pfizer Inc.
• GSK plc
• Novartis AG
• AstraZeneca Inc.
• Johnson & Johnson
• Sun Pharmaceutical Industries Ltd.
• Merck & Co., Inc.

Report Scope:

This report segments the Global Lower Respiratory Tract Therapeutics Market into the following categories, with detailed industry trends:

By Disease Type:

• Asthma
• COPD
• Pneumonia
• Tuberculosis
• Bronchitis
• Others

By Drug Class:

• Antibiotics
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Cough Suppressants
• Nasal Decongestants
• Others

By Route of Administration:

• Oral
• Parenteral
• Others

By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

By Region:

• North America (United States, Canada, Mexico)
• Europe (France, United Kingdom, Italy, Germany, Spain)
• Asia-Pacific (China, India, Japan, Australia, South Korea)
• South America (Brazil, Argentina, Colombia)
• Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape:

Company Profiles: This section provides a detailed analysis of the major companies operating in the Lower Respiratory Tract Therapeutics Market.

Available Customizations:

The Global Lower Respiratory Tract Therapeutics Market report offers customizations tailored to the specific needs of a company. The following customization options are available:

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Applications
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Lower Respiratory Tract Therapeutics Market

5. Voice of Customer

6. Global Lower Respiratory Tract Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type (Asthma, COPD, Pneumonia, Tuberculosis, Bronchitis, Others)
  • 6.2.2. By Drug Class (Antibiotics, Non-Steroidal Anti-Inflammatory Drugs, Cough Suppressants, Nasal Decongestants, Others)
  • 6.2.3. By Route of Administration (Oral, Parenteral, Others)
  • 6.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centres, Others)
  • 6.2.5. By Region
  • 6.2.6. By Company (2024)
• 6.3. Market Map

7. Asia Pacific Lower Respiratory Tract Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Route of Administration
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Asia Pacific: Country Analysis
  • 7.3.1. China Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End User
  • 7.3.2. India Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End User
  • 7.3.3. Australia Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End User
  • 7.3.4. Japan Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By End User
  • 7.3.5. South Korea Lower Respiratory Tract Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By End User

8. Europe Lower Respiratory Tract Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Route of Administration
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End User
  • 8.3.2. Germany Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End User
  • 8.3.3. Spain Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End User
  • 8.3.4. Italy Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By End User
  • 8.3.5. United Kingdom Lower Respiratory Tract Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By End User

9. North America Lower Respiratory Tract Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Route of Administration
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. North America: Country Analysis
  • 9.3.1. United States Lower Respiratory Tract Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End User
  • 9.3.2. Mexico Lower Respiratory Tract Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End User
  • 9.3.3. Canada Lower Respiratory Tract Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End User

10. South America Lower Respiratory Tract Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Drug Class
  • 10.2.3. By Route of Administration
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lower Respiratory Tract Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By End User
  • 10.3.2. Argentina Lower Respiratory Tract Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By End User
  • 10.3.3. Colombia Lower Respiratory Tract Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By End User

11. Middle East and Africa Lower Respiratory Tract Therapeutics Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Disease Type
  • 11.2.2. By Drug Class
  • 11.2.3. By Route of Administration
  • 11.2.4. By End User
  • 11.2.5. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Lower Respiratory Tract Therapeutics Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Disease Type
      • 11.3.1.2.2. By Drug Class
      • 11.3.1.2.3. By Route of Administration
      • 11.3.1.2.4. By End User
  • 11.3.2. Saudi Arabia Lower Respiratory Tract Therapeutics Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Disease Type
      • 11.3.2.2.2. By Drug Class
      • 11.3.2.2.3. By Route of Administration
      • 11.3.2.2.4. By End User
  • 11.3.3. UAE Lower Respiratory Tract Therapeutics Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Disease Type
      • 11.3.3.2.2. By Drug Class
      • 11.3.3.2.3. By Route of Administration
      • 11.3.3.2.4. By End User

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Product Launches
• 13.3. Mergers & Acquisitions

14. Global Lower Respiratory Tract Therapeutics Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

• 17.1. F. Hoffman - La Roche Ltd
  • 17.1.1. Business Overview
  • 17.1.2. Company Snapshot
  • 17.1.3. Products & Services
  • 17.1.4. Financials (In case of listed companies)
  • 17.1.5. Recent Developments
• 17.2. Teva Pharmaceutical Industries Ltd.
• 17.3. Sanofi S.A
• 17.4. Pfizer Inc.
• 17.5. GSK plc
• 17.6. Novartis AG
• 17.7. AstraZeneca
• 17.8. Johnson & Johnson
• 17.9. Sun Pharmaceutical Industries Ltd.
• 17.10. Merck & Co., Inc

18. Strategic Recommendations

19. About Us & Disclaimer